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Abstract Cardiac physiology and hypertrophy are regu-
lated by the phosphorylation status of many proteins, which
is partly controlled by a poorly defined type 2A protein
phosphatase-alpha4 intracellular signalling axis. Quantita-
tive PCR analysis revealed that mRNA levels of the type
2A catalytic subunits were differentially expressed in H9c2
cardiomyocytes (PP2ACb[PP2ACa[PP4C[PP6C),
NRVM (PP2ACb[ PP2ACa = PP4C = PP6C), and
adult rat ventricular myocytes (PP2ACa[
PP2ACb[ PP6C[ PP4C). Western analysis confirmed
that all type 2A catalytic subunits were expressed in H9c2
cardiomyocytes; however, PP4C protein was absent in
adult myocytes and only detectable following 26S protea-
some inhibition. Short-term knockdown of alpha4 protein
expression attenuated expression of all type 2A catalytic
subunits. Pressure overload-induced left ventricular (LV)
hypertrophy was associated with an increase in both
PP2AC and alpha4 protein expression. Although PP6C
expression was unchanged, expression of PP6C regulatory
subunits (1) Sit4-associated protein 1 (SAP1) and (2)
ankyrin repeat domain (ANKRD) 28 and 44 proteins was
elevated, whereas SAP2 expression was reduced in
hypertrophied LV tissue. Co-immunoprecipitation studies
demonstrated that the interaction between alpha4 and
PP2AC or PP6C subunits was either unchanged or reduced
in hypertrophied LV tissue, respectively. Phosphorylation
status of phospholemman (Ser63 and Ser68) was signifi-
cantly increased by knockdown of PP2ACa, PP2ACb, or
PP4C protein expression. DNA damage assessed by histone
H2A.X phosphorylation (cH2A.X) in hypertrophied tissue
remained unchanged. However, exposure of cardiomy-
ocytes to H2O2 increased levels of cH2A.X which was
unaffected by knockdown of PP6C expression, but was
abolished by the short-term knockdown of alpha4 expres-
sion. This study illustrates the significance and altered
activity of the type 2A protein phosphatase-alpha4 com-
plex in healthy and hypertrophied myocardium.
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Introduction
Serine/threonine protein phosphatases and kinases control
the phosphorylation status of many substrates and, as a
consequence, regulate their activity and/or cellular locali-
sation. The serine/threonine protein phosphatases comprise
a relatively large family of enzymes that are ubiquitously
expressed and can be further subdivided into PP1, PP2A,
PP2B (calcineurin), PP2C, PP3, PP5, and PP7 families
based on their sensitivity to inhibitors such as okadaic acid
[15] and their metal ion-dependent activity [14, 33]. The
type 2A protein phosphatase (PP2A) family, named after
the first member of this family (PP2A) to be cloned [2],
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was later found to be comprised of highly homologous PP4
(PPX) and PP6 (PPV) catalytic subunit proteins [15]. The
catalytic subunits (C) are responsible for conferring phos-
phatase enzyme activity towards a plethora of substrates.
However, despite the high sequence homology between the
type 2A phosphatase catalytic subunits ([50%), there is
very little similarity between the mechanisms that control
their cellular activity and localisation.
To avoid indiscriminate phosphatase activity, PP2AC
subunits do not exist as ‘‘free’’ monomers in the cytosol,
but are usually associated with other regulatory proteins
and consequently, PP2AC can exist in several discreet
heteromeric populations. In its simplest form, the catalytic
subunit associates with a scaffold (A) subunit to form a
heterodimeric core enzyme [43, 68] that constitutes
approximately a third of total PP2A in the cell [43]. Fur-
thermore, the scaffold A- and C-subunits are expressed in
varying degrees as a and b isoforms [3, 27, 30]; however,
the complexity of activity towards substrates is largely
controlled by the association of the heterodimeric core
enzyme with a non-catalytic regulatory/targeting B subunit
to form the active heterotrimeric holoenzyme [36]. The B
subunits are themselves subdivided into four distinct gene
families that give rise to the B, B0, B00, and B000 subfamilies
[36] encoded by 15 different human genes giving rise to at
least 23 different isoforms (reviewed by Sents et al. [72]).
The architecture of the heterotrimeric PP2A complex can
result in at least 96 distinct holoenzymes [37].
It is clear that the activity and localisation of type 2A
protein phosphatase catalytic subunits are regulated by
their association with a myriad of accessory proteins. One
such atypical regulatory subunit for the type 2A phos-
phatases, namely alpha4, was first cloned from B-lym-
phocytes as an immunoglobulin binding protein [34] and
then later identified as tap42 in yeast [19]. Several studies
have shown alpha4 to associate with all type 2A protein
phosphatase C-subunits [11, 44, 54–56]. The association
between alpha4 and the type 2A protein phosphatases was
considered to be inhibitory in nature [35, 56]; however, this
appears to be dependent on the substrate being dephos-
phorylated by the C-subunit/alpha4 heterodimer [63].
Recent studies have revealed that alpha4 plays a critical
role in controlling the ubiquitination state and levels of
PP2AC [41, 50, 82]. Hence, an additional consequence of
the association between alpha4 and type 2A protein phos-
phatase catalytic subunits involves the ‘‘protection’’ of
C-subunits from polyubiquitination and consequent 26S
proteasome-mediated degradation [41]. A functional con-
sequence of this type 2A catalytic subunit-alpha4 interac-
tion was demonstrated by the genetic ablation of alpha4
protein expression, which induced the loss of type 2A
C-subunit expression and apoptotic cell death in a number
of cell types [41, 42].
Protein phosphatase 4 (PP4), the eukaryotic homologue
of yeast Pph3p, is regulated by its association with a family
of regulatory proteins termed R1–R4 [10, 26, 28, 40].
Evidence suggests that an active unit of the PP4 phos-
phatase can be comprised of either a simple heterodimer of
PP4C and R1/R2 (low activity) or an active heterotrimer
with any two of the aforementioned regulatory subunits
[16, 26]. In addition, the R2 subunit is thought to confer
cisplatin resistance in mammalian cells [29]. Furthermore,
the R3 regulatory subunit can be subdivided into two clo-
sely related homologues a and b, of which the R3a isoform
is overexpressed in breast and lung cancers [81]. The last
PP4C regulatory subunit to have been characterised R4/
KIAA1622 does not appear to ‘‘bridge’’ the association of
PP4C with any of the other regulatory subunits [10].
The PP6C subunit was first cloned in budding yeast as
sit4p [4]. Regulation of PP6C in mammalian cells is con-
trolled by its association with SAP1-3 [47] and ANKRD28,
44 or 52 [77]. One of many several cellular functions
ascribed to PP6C indicates that SAP1 facilitates PP6C-
mediated dephosphorylation and activation of DNA protein
kinase (DNA-PK) [31, 51], which then phosphorylates
H2A.X at Ser139 [53, 60, 78]. Phosphorylated H2AX
(cH2AX) is required for the recruitment of DNA repair
proteins [61] and eventual repair of DNA double-strand
breaks by non-homologous end-joining (NHEJ) [20]. SAP2
and SAP3 proteins have been suggested to play a role in
cell cycle-related mTORC1-PP6 signalling events in yeast
[52] and homology-directed repair of DNA in cancerous
tissue [84]. The ANKRD proteins share [58% overall
sequence identity, where the N-terminal 400 amino acids
are almost 100% conserved and the C-terminal tail contains
stretches of conserved/non-conserved amino acid sequen-
ces that contribute to the highest variability between iso-
forms [76]. Reported functionality of the ANKRD28
protein is limited to being involved in dephosphorylation of
the inhibitory subunit of nuclear factor jB epsilon (IjBe)
in response to TNFa [76], and more recently, it was found
to associate with the tumour suppressor protein BRCA1
[80]. The cellular functions for the other ANKRD regula-
tory proteins (44 and 52) remain poorly defined.
As in many other tissues, the regulation of PP2A in
cardiac health and disease has been explored
[18, 25, 57, 58], but relatively little is understood regarding
the regulation of PP4C and PP6C in the heart. PP4C protein
expression was first identified in cardiac tissue by Kloeker
and colleagues albeit at very low levels in comparison to
PP2AC [39]. However, abundant PP6C expression was
identified in heart tissue almost 20 years ago by Bastians
and Ponstingl [5]. Since these studies, very little has been
reported regarding the expression/regulation of PP4C and
PP6C in the healthy or diseased heart. The main objectives
of the present study were to determine the expression and
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regulation of the type 2A protein phosphatase catalytic
subunit/alpha4 intracellular signalling axis in the healthy
and diseased myocardium.
Methods and materials
Animal tissue used in this study was obtained in accor-
dance with the UK Home Office Guidance on the Opera-
tion of the Animals (Scientific Procedures) Act 1986 (UK),
the Directive of the European Parliament (2010/63/EU),
and received approval by the local ethics review board at
King’s College London. Healthy animals were killed by a
schedule one procedure completed by a home office
licensed individual, such that animal suffering was cate-
gorised as minimal.
Materials
Sheep polyclonal anti-PP2AC, -PP4C, and -PP6C anti-
bodies were described previously [39]. Primary antibodies
to detect SAP1 (V-14), SAP2 (H-43), procaspase 3 (H-
277), and actin (I-19) were purchased from Santa Cruz
Biotechnologies (USA), whereas the anti-SAP3 antibody
was purchased from ProteintechTM (USA). Antibody to
detect ANKRD28 was purchased from Bethyl Laboratories
(USA), whereas antibodies to detect ANKRD44 and
ANKRD52 were purchased from LifeSpan Biosciences Inc
(USA). Rabbit polyclonal anti-alpha4 antibody (A300-
417A) was purchased from Bethyl Laboratories (USA),
whereas the mouse monoclonal anti-alpha4 (5F6), rabbit
monoclonal anti-cH2A.X (Ser139), rabbit polyclonal anti-
H2A.X, and rabbit polyclonal anti-PARP1 antibodies were
obtained from Cell Signaling Technology (USA). Whole
rabbit IgG was purchased from Sigma-Aldrich (UK). HRP-
conjugated donkey anti-goat and anti-sheep secondary
antibodies were purchased from Santa Cruz Biotechnolo-
gies. HRP-conjugated donkey/goat anti-rabbit and sheep/
horse anti-mouse secondary antibodies were purchased
from either GE Healthcare (UK) or Cell Signaling Tech-
nology, respectively. Antibodies to phosphorylated (Ser63
and Ser68) or non-phosphorylated phospholemman were
either custom-made and a kind gift from Professor MJ
Shattock [24] or obtained from Abcam (#200204),
respectively. Anti-actin primary antibody was detected
using a donkey IRDye680RD anti-goat secondary anti-
body purchased from LI-COR (UK). Protein A paramag-
netic beads were purchased from Cell Signaling
Technology. RNA extraction was performed using an
RNeasyProtect cell mini kit and QIAshredder homoge-
nizer (Qiagen, UK). Agilent RNA 6000 Nano kit was
purchased from Agilent Technologies, USA. Verified
quantitative PCR primer pairs were obtained from
Primerdesign Ltd., UK, and included: rat PP2ACa forward
primer 50-TTACCGAGAGCGTATCACCATA-30 and
reverse primer 50-TTTCCGTATTTCCTTAAACACTC
ATC-30; PP2ACb forward 50-TCGTGACTGGTTAAGG-
GAAAGG-30 and reverse 50-AAACTCCAACT CTA-
TAATCCATGCC-30; PP4C forward 50-TGACATCCACG
GACAATTCTATG-30 and reverse 50-CAGCAGGAG
GAGGAAGGTTT-30; PP6C forward 50-GGCT
TGTTCTTCCTAAAATGGC-30 and reverse 50-TTCCAA
GAGCAGATCACAAA CATA-30; and b-actin (accession
number: NM_031144). All other qRT-PCR reagents
(NanoScript 2 Reverse Transcription kit, PrecisionTM2X
qPCR Mastermix) were also purchased from Primerdesign
Ltd., UK. ON-TARGETplus SMARTpool rat-specific
siRNA to alpha4 and PP6C, as well as ON-TARGETplus
non-targeting control pool siRNA, were purchased from
GE Healthcare UK (Dharmacon).
H9c2 cardiomyocyte cell culture
H9c2 cardiomyocytes were obtained from ATCC
(#CRL-1446TM) and grown in DMEM (Life Technolo-
gies) supplemented with 10% FBS (Life Technologies),
penicillin 100 IU/mL, and streptomycin 100 lg/mL.
Cells were grown at 37 C in humidified 5% CO2/95%
air until 80% confluent and were then either passaged or
processed for analysis of gene expression by quantitative
RT-PCR. Furthermore, H9c2 cardiomyocytes were also
treated with either MG132 or H2O2 for 24 h followed by
lysis with Laemmli sample buffer and western analysis.
H9c2 cardiomyocytes cultured for PP6C and alpha4
knockdown studies were initially seeded at *30% con-
fluency and incubated with an appropriate amount of
siRNA.
Isolation and cell culture of neonatal rat ventricular
myocytes (NRVMs)
Neonatal rat ventricular myocytes were isolated and cul-
tured as previously described [64]. In brief, NRVM were
isolated from 1–2-day-old Sprague–Dawley rats by colla-
genase-pancreatin digestion. Cells were plated at a density
of *2 9 106 cells per well on gelatin-coated 6-well cul-
ture plates (Nunclon) and maintained in medium contain-
ing DMEM:M199 (4:1) supplemented with 5% FCS, 10%
horse serum, and 1% penicillin/streptomycin for 24 h.
Fibroblast growth was inhibited by the addition of 20 lM
cytosine arabinoside (Sigma-Aldrich). NRVM were either
cultured for 48 h prior to western analysis or processed for
RNA extraction and analysis of gene expression by quan-
titative RT-PCR.
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Isolation and cell culture of adult rat ventricular
myocytes (ARVMs)
ARVM were isolated from the hearts of adult male Wistar
rats (200–250 g, B&K Universal Ltd.) by collagenase-
based enzymatic digestion, as previously described [74].
ARVM were then allowed to rest for 2 h post-isolation to
form a pellet, followed by a brief centrifugation at
50g. Storage medium was then removed and the ARVM
pellet was resuspended in sterile PBS prior to being cul-
tured according to previously described protocols [73, 74].
Freshly isolated ARVM were either cultured for 24 h prior
to treatment and western analysis or processed for RNA
extraction and analysis of gene expression by quantitative
RT-PCR.
Determination of type 2A protein phosphatase
catalytic subunit gene expression by quantitative
RT-PCR
Freshly isolated ARVM, cultured NRVM, or H9c2 car-
diomyocytes were harvested and centrifuged at 100g for
3 min at room temperature. Cell pellets (1–2 9 106 cells)
were either immediately resuspended in RNAprotect cell
reagent at room temperature following the manufacturer’s
instructions and processed immediately for RNA extraction
or stored long term at -20 C. Total RNA was isolated
from cells using the RNeasy protect cell mini kit according
to the manufacturer’s protocol. Cellular homogenization
was performed by QIAShredder spin columns. All RNA
samples were subjected to only one freeze–thaw cycle.
Total RNA purity and quantity was assessed by obtaining
the RNA integrity number (RIN) from cardiomyocyte
samples using the Agilent RNA 6000 Nano kit and the
Agilent 2100 Bioanalyzer system (Agilent Technologies,
USA). H9c2 and ARVM samples with a RIN between 9
and 10 and between 7 and 9, respectively, were selected for
subsequent qPCR analysis [23]. Depending on the RNA
concentration, 500 ng or 1 lg of total RNA was reverse
transcribed into cDNA using oligo-dT primers via a two-
step reverse transcription process using the NanoScript 2
reverse transcription kit (PrimerDesign Ltd., UK) and used
according to the manufacturer’s instructions. cDNA was
diluted to 5 ng/lL and stored at -20 C. All qPCR reac-
tions were performed in a Stratagene Mx3005P qPCR
system (Agilent Technologies, USA) using PrecisionTM2X
MasterMix according to the manufacturer’s instructions.
Each reaction contained 5 lL diluted cDNA (25 ng in
total), 10 lL PrecisionTM29 qPCR MasterMix, 1 lL pri-
mer mix (300 nM final concentration), and 4 lL RNAse/
DNAse free water. A non-reverse transcriptase control
(NRT) and a non-template control (NTC) were included as
negative controls for each gene. The qPCR conditions were
as follows: 10 min at 95 C, followed by 40 cycles of 15 s
at 95 C and 1 min at 60 C. Fold change in mRNA levels
was calculated using the comparative CT method [70] and
expressed relative to PP2ACa mRNA levels. Values were
expressed as the averaged quantification cycle (Cq) value
of each gene normalised to the averaged Cq values for
reference gene b-actin. The mean Cq accepted standard
deviation (SD) was B0.15 cycles. All data are presented in
accordance with MIQE guidelines on the minimum infor-
mation for publication of quantitative real-time PCR
experiments [9].
Knockdown of protein expression in H9c2
cardiomyocytes by siRNA
H9c2 cardiomyocytes were cultured as described above in
6-well plates with a subcultivation ratio of 1:10 and were
then maintained in DMEM culture medium supplemented
with 10% FBS, penicillin 100 IU/mL and streptomycin
100 lg/mL at 5% CO2/37 C until they reached 30%
confluency. Cultured H9c2 cardiomyocytes were incubated
with ON-TARGETplus SMARTpool rat alpha4, PP6C
specific siRNA, or ON-TARGETplus non-targeting control
pool siRNA. The transfection mix was prepared using a
ratio of 1 lL of DharmaFECT(#1):50 pmol of siRNA and
allowed to incubate on ice for 20 min to form
siRNA:DharmaFECT complexes. The transfection mix was
then combined with an appropriate volume of antibiotic-
free DMEM containing 10% FBS to achieve a final siRNA
concentration of 50 nM. Transfected H9c2 cardiomyocytes
were incubated at 37 C in 5% CO2 for 1–8 days. The
transfection medium was replaced and cells re-transfected
every 4 days when silencing PP6C protein expression for
up to 8 days. The cells were then lysed with 19 Laemmli
sample buffer for subsequent western analysis.
Pressure overload-induced murine hypertrophy
Myocardial hypertrophy was induced as previously
described by Boguslavskyi et al. [6]. In brief, pressure
overload was induced by suprarenal transaortic constriction
(TAC) in 6-week-old C57BL/6J mice (20–22 g). The
reproducibility of the transaortic constriction was assured
by placing a suture around the abdominal aorta and a
28-gauge blunted needle, which was then subsequently
removed. The suture remained in place for 4 weeks after
which the animals were killed and the hearts excised,
whereupon the LV free wall was dissected away and pro-
cessed for subsequent protein analysis. Hypertrophic
growth was expressed as a ratio of LV tissue to tibia length.
Sham animals were treated identically except that the
suture around the aorta was not tied in place. For all sur-
gical procedures, mice were anaesthetized by inhalation of
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isoflurane/O2 mixture (2/98%). Adequacy of anaesthesia
was controlled by monitoring corneal reflex and respiration
(rate, depth, and pattern of breathing). Acute postoperative
analgesia was a single buprenorphine (Vetergesic 0.3 mg/
mL solution) injected i.p. at dose 20 mg/kg. Euthanasia
was performed by overdose of isoflurane. Death was con-
firmed by monitoring cardiac activity and respiration. Heart
excision for homogenisation and tissue lysate preparation
was performed after terminal anaesthesia by i.p. injection
of pentobarbital (Pentoject 200 mg/mL solution) at dose
300 mg/kg and heparin (150 U).
Preparation of murine ventricular tissue for protein
analysis
The excised heart was rapidly flushed with ice-cold PBS to
remove any residual blood and extraneous tissue was then
removed. The LV free wall was dissected away and immedi-
ately placed into liquid nitrogen for short-term storage. LV
tissue was homogenised on ice (100 mg tissue/ml of buffer) in
ice-cold homogenisation buffer containing; 20 mM MOPS,
140 mM NaCl, 5 mM KCl, 1 mM EDTA, phosphatase inhi-
bitor cocktail #3 (Sigma-Aldrich, UK), and protease inhibitor
cocktail set 3 (Calbiochem, UK). Homogenates were diluted
(1:1) with 29 Laemmli sample buffer for subsequent western
analysis or frozen at -80 C for subsequent immunoprecipi-
tation of alpha4 protein. The protein content of tissue homo-
genates was adjusted to 500 lg/mL with ice-cold lysis buffer;
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4,
20 mMTris–HCl, 1%Triton X-100, 1 lg/mL leupeptin, mini-
Complete protease inhibitor cocktail (Roche, UK), and pH 7.5.
Cell lysates were incubated on ice for 5 min and centrifuged at
14,000g at 4 C for 30 min to separate the triton-soluble frac-
tion (supernatant) from the triton-insoluble particulate fraction
(pellet). An aliquot of the solubilised fraction was removed for
subsequent western analysis of protein expression in the input
pre immunoprecipitation (pre-IP) lysate. To the remaining
solubilised lysate 2 lL (1 lg/lL) of rabbit IgG, 2 lL PBS, or
2 lL (1 lg/lL) of rabbit polyclonal anti-alpha4 antibody was
added. The addition of rabbit IgG or PBS was to test for non-
specific binding of IgG or protein A to alpha4 protein,
respectively. All samples were then incubated with gentle
inversion overnight at 4 C. Each tubewas then incubatedwith
40 lL of protein A paramagnetic bead slurry for 2 h at 4 C.
The immunoprecipitate complex was then washed three times
with ice-cold cell lysis buffer and then resuspended in 50 lL of
39 Laemmli sample buffer.
Western analysis
Cultured cells were rinsed with ice-cold PBS and then lysed
with 19 Laemmli sample buffer unless otherwise stated.
Western analysis was carried out as previously described
[75]. In brief, protein samples were separated by 10.5–15%
SDS-PAGE, transferred to PVDF (0.2 or 0.45 lm pore size)
or nitrocellulose membranes where appropriate and probed
with primary antibodies. To confirm equal protein loading in
each sample, actin content was determined using an anti-
actin primary antibody which was detected using a donkey
anti-goat IRDye680RD secondary antibody followed by
image acquisition and quantification using an LI-COR
Odyssey CLx system. Where appropriate, primary antibod-
ies were detected using donkey anti-sheep or anti-goat;
donkey or goat anti-rabbit; sheep or horse anti-mouse sec-
ondary antibodies (1:1000) linked to HRP. Specific protein
bands were detected by enhanced chemiluminescence (GE
Healthcare, UK) and band intensity was quantified using a
calibrated GS-800 densitometer and Quantity One 1-D
analysis software v4.6.2 (Bio-Rad, UK). Equal protein
loading was determined either by quantifying the content of
non-phosphorylated protein (where appropriate) or actin
within each sample, which unless otherwise stated was used
to normalise the expression of all other proteins of interest.
Statistical analysis
Data are presented as mean ± SEM. Where appropriate,
data were subjected to either an unpaired Student’s t test or
ANOVA (GraphPad Prism v6.0.1) to test for significant
differences (P\ 0.05) between groups. Further multiple
group comparison was completed using either a Dunnett’s
or Tukey’s modified t test.
Results
Expression of type 2A phosphatase catalytic
subunits in cardiomyocytes
The expression of type 2A protein phosphatase catalytic
subunits was determined at both the mRNA and protein
level in rat embryonic H9c2 cardiomyocytes, neonatal rat
ventricular myocytes (NRVM), and adult rat ventricular
myocytes (ARVM). Data confirm that gene transcription of
all type 2A protein phosphatases was active in H9c2 car-
diomyocytes (Fig. 1a), NRVM (Fig. 1b), and ARVM
(Fig. 1c), as mRNA was detected for all type 2A phos-
phatases. PP2ACb mRNA expression seemed to be most
abundant in both H9c2 cardiomyocytes and NRVM,
whereas PP2ACa mRNA appeared to be most abundant in
ARVM. PP4C mRNA expression was[14-fold less than
PP2ACa mRNA in ARVM. All three type 2A catalytic
subunits were expressed at the protein level in H9c2 car-
diomyocytes (Fig. 1c–f) and NRVM (Supplemental Fig-
ure S1); however, we could not detect any PP4C protein
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expression in ARVM (Fig. 1f). Furthermore, PP6C
expression was significantly higher in ARVM than in H9c2
cardiomyocytes (Fig. 1g). The selectivity of the antibodies
towards specific type 2A protein phosphatase catalytic
subunits was confirmed by siRNA-mediated knockdown of
PP2ACa (Supplemental Figure S2), PP2ACb (Supple-
mental Figure S3), PP4C (Supplemental Figure S4), or
PP6C (Supplemental Figure S5) in H9c2 cardiomyocytes
followed by western analysis to determine the expression
levels of the other type 2A protein phosphatase catalytic
subunits. These data suggest that there is differential
expression of PP2AC, PP4C, and PP6C at both the mRNA
and protein level in cardiac tissue.
Role of the 26S proteasome in type 2A protein
phosphatase catalytic subunit expression in ARVM
One possible explanation why PP4C protein expression was
undetectable in cultured ARVM, despite expression of PP4C
mRNA, could be that it is subject to excessive proteasomal
degradation. To test this idea, we treated ARVM with
MG132 (1 lM) to inhibit proteasome activity, which was
confirmed by progressively elevated levels of protein ubiq-
uitination from 0 to 24 h (Fig. 2a). The western analysis data
(Fig. 2b) and quantification by densitometry (Fig. 2c–e)
suggest that the expression level of type 2A protein phos-
phatases in ARVM was differentially regulated by the 26S
proteasome. The expression of PP2ACandPP6Cproteinwas
not significantly altered by MG132-mediated inhibition of
the 26S proteasome for 24 h. However, PP4C expression
which was undetectable in untreated ARVM, increased
significantly (P\ 0.05) following 4 and 8 h of 26S protea-
some inhibition with 1 lM MG132 (Fig. 2d). These data
indicate that the apparent absence of PP4C protein expres-
sion in the adult myocardium may have been due (in part) to
proteasome-mediated degradation of PP4C.
Regulation of type 2A phosphatase catalytic subunit
expression by alpha4
To investigate whether the non-catalytic type 2A protein
phosphatase regulatory protein alpha4 modulates type 2A
Fig. 1 Expression of type 2A protein phosphatase catalytic subunits
in H9c2 cardiomyocytes and ARVM. qRT-PCR determination of type
2A protein phosphatase catalytic subunit mRNA expressed as fold
change relative to PP2ACa and normalised to b-actin in cultured
H9c2 cardiomyocytes (a) and freshly isolated ARVM (b). Protein
expression of type 2A protein phosphatase catalytic subunits was
determined by western analysis with subunit-specific antibodies to
PP2AC, PP4C, and PP6C (c). Levels of phosphatase catalytic subunit
expression from cultured H9c2 and freshly isolated ARVM lysates
were quantified by densitometry and normalised to actin (d–f). All
data represent mean values ± SEM of three individual experiments,
*P\ 0.05
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protein expression in cardiomyocytes as previously repor-
ted in mouse embryonic fibroblasts [41], the expression of
alpha4 protein was knocked down in H9c2 cardiomyocytes
using rat alpha4-specific siRNA (si) for 1–4 days. Alpha4
protein expression was significantly (P\ 0.05) decreased
by *95% following 4 days of transfection with alpha4-
specific siRNA when compared to control cells (Fig. 3a).
Interestingly, knockdown of alpha4 in H9c2 cardiomy-
ocytes significantly (P\ 0.05) reduced the expression of
all type 2A protein phosphatase catalytic subunits (PP2AC,
PP4C, and PP6C) by 84, 78, and 74%, respectively, when
compared to non-targeting control (Fig. 3b). These data
confirm that alpha4 is, indeed, involved in the regulation of
type 2A protein phosphatase expression/biogenesis in
cardiomyocytes.
Expression of the type 2A phosphatase-alpha4
signalling axis in left ventricular hypertrophy
Four weeks of TAC-mediated pressure overload induced a
*60% increase in LV weight when expressed relative to
tibia length (Fig. 4a). Further indices of hypertrophy (heart
weight/body weight, heart weight/tibia length, and LV
weight/body weight) were also determined (Supplemental
Figure S6). Western analysis revealed that the expression
of type 2A protein phosphatases was differentially altered
in LV hypertrophied tissue (Fig. 4b). PP2AC protein
expression in LV hypertrophied tissue was significantly
(P\ 0.05) higher (1.7-fold) than in non-hypertrophied LV
SHAM control tissue (Fig. 4c). However, expression of
PP4C was undetectable in mouse LV tissue (Fig. 4d), again
confirming the absence of PP4C protein expression in adult
myocardial tissue as previously observed in ARVM
(Fig. 1e). No differences in PP6C protein expression were
observed in lysates of LV tissue obtained from hearts of
SHAM and TAC-operated mice (Fig. 4e). Interestingly,
expression of alpha4 protein was significantly (P\ 0.05)
elevated (1.8-fold) in hypertrophied LV tissue when com-
pared to LV tissue obtained from SHAM control hearts
(Fig. 4f).
Expression of PP6C regulatory proteins in left
ventricular hypertrophy
The regulation of PP6C subcellular localisation and activ-
ity is achieved by the association of the C-subunit with an
SAP and ANKRD protein [77]. Data in Fig. 5a show
changes in SAP1-3 protein expression, in response to TAC-
induced LV hypertrophy. Quantification of these data
revealed that SAP1 (Fig. 5b) and SAP2 (Fig. 5c) protein
expression was either significantly (P\ 0.05) increased
(2.2-fold) or decreased (2.8-fold) in the hypertrophied left
ventricle, respectively. SAP3 protein expression, unlike
SAP1 and SAP2, was unchanged (Fig. 5d). Furthermore,
expression of the PP6C regulatory proteins ANKRD28/44/
52 in LV hypertrophied tissue was also differentially
altered (Fig. 5e). Expression of ANKRD28 (Fig. 5f) and
ANKRD44 (Fig. 5g) proteins was both significantly
(P\ 0.05) elevated 1.9- and 1.5-fold, respectively,
whereas expression of ANKRD52 protein (Fig. 5h)
remained unchanged in hypertrophied LV tissue. Despite
the protein expression of PP6C not being altered in
hypertrophied LV tissue (Fig. 4e), these data support a
novel observation which suggests that there are differential
Fig. 2 Proteasomal degradation of type 2A protein phosphatase
catalytic subunits in ARVM. Cultured ARVM were exposed to
MG132 (1 lM) for 0, 2, 4, 8, and 24 h. Ubiquitination of proteins was
determined by western analysis using an anti-ubiquitin antibody (a).
Effect of 26S proteasome inhibition on the expression of type 2A
protein phosphatase catalytic subunits was determined by western
analysis using subunit-specific antibodies to PP2AC, PP4C, and PP6C
(b) and then quantified by densitometry (c–e). Data are representative
of three individual experiments and represent mean values ± SEM,
*P\ 0.05 vs. untreated control
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changes in the expression of the PP6C regulatory SAP and
ANKRD proteins in hypertrophied LV tissue.
Association of alpha4 protein with type 2A protein
phosphatase catalytic subunits in hypertrophied left
ventricular tissue
The association of type 2A protein phosphatase catalytic
subunits with alpha4 was investigated through co-im-
munoprecipitation of alpha4 and C-subunit protein com-
plexes from SHAM- or TAC-operated mouse LV tissue
lysates using a polyclonal alpha4 antibody. The protocol
that we developed for immunoprecipitating alpha4 from
LV tissue lysate depleted[95% of alpha4 protein from cell
lysates (Fig. 6a). Furthermore, significantly (P\ 0.05)
higher alpha4 content was detected in immunocomplexes
from LV hypertrophied tissue when compared to SHAM
control LV tissue (Fig. 6b), probably due to the signifi-
cantly higher level of alpha4 protein expression in LV
tissue. Consequently, to accurately determine whether the
association of PP2AC or PP6C protein with alpha4 protein
was altered in hypertrophied tissue, the quantitation of
PP2AC and PP6C in the alpha4 immunocomplex was
normalised to the amount of alpha4 protein present.
Immunoprecipitation of alpha4 protein from murine LV
tissue significantly (P\ 0.05) reduced the content of both
PP2AC protein (Fig. 6c) and PP6C protein (Fig. 6d) in the
post-IP lysate to 62.8 ± 13.2 and 52.0 ± 11.4%, respec-
tively, when compared to the pre-IP ‘‘input’’ lysate. The
alpha4 immunocomplexes were then probed with a PP2AC
subunit-specific antibody and although the alpha4
immunocomplexes contain PP2AC protein, no differences
in the association between PP2AC and alpha4 protein were
observed between SHAM and TAC (hypertrophied) LV
tissue (Fig. 6e). Hence, our data suggest that even though
alpha4 protein associates with a significant proportion of
PP2AC protein (37%) in cardiac tissue, this association is
not affected by pressure overload-induced LV hypertrophy.
Furthermore, when the same alpha4 immunoprecipitates
from LV tissue lysates of SHAM- and TAC-operated mice
were probed for PP6C content, we observed significantly
(P\ 0.05) less PP6C protein (30.4 ± 7.6%) within the
immunoprecipitates from hypertrophied tissue, when
compared to SHAM control tissue (Fig. 6f). These data not
only show that alpha4 protein associates with a significant
proportion (48%) of PP6C protein in cardiac tissue, but that
this association is significantly reduced in hypertrophied
tissue. Hence, our novel data demonstrate that alpha4
protein differentially associates with PP2AC and PP6C
catalytic subunits in hypertrophied LV tissue.
Regulation of phospholemman phosphorylation
by type 2A protein phosphatases in cardiomyocytes
Phospholemman (PLM) is a phosphoprotein and a negative
regulator of sarcolemmal Na?/K?-ATPase (sodium pump)
activity in the heart (as reviewed by Pavlovic et al. [62]).
Phosphorylation of PLM at Ser63/Ser68 underpins the
inhibition of its activity towards the sodium pump and its
hypophosphorylation at these two sites has been implicated
to play a role in the development of cardiac hypertrophy
[6]. Historically, the use of non-specific and non-selective
Fig. 3 Regulation of type 2A protein phosphatase catalytic subunit
expression by alpha4 in cardiomyocytes. H9c2 cardiomyocytes were
incubated with either 50 nM non-targeting control siRNA (ctr) or
50 nM rat alpha4-specific siRNA (si) for 1–4 days to silence the
expression of alpha4 protein which was confirmed by western
analysis with a polyclonal alpha4 specific antibody (a). Expression of
type 2A protein phosphatase catalytic subunits (PP2AC, PP4C and
PP6C) was then determined in H9c2 cardiomyocytes using type 2A
phosphatase catalytic subunit-specific antibodies and western analysis
following siRNA-driven knockdown of alpha4 protein expression for
4 days (b). Equal protein loading was confirmed by the determination
and then normalisation to actin in each sample. All data are
representative of four individual experiments and represent mean
values ± SEM, *P\ 0.05 vs. ctr
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protein phosphatase inhibitors has been used to implicate a
role for PP2AC in dephosphorylating PLM in the heart
[59]. However, using subunit selective siRNA molecules to
knockdown the expression of each individual type 2A
catalytic subunit, our study shows that PLM phosphoryla-
tion at both Ser63 and Ser68 was significantly elevated
when expression of either alpha (331.7 ± 79.0,
471.0 ± 145.2%) or beta (386.4 ± 76.3, 408.4 ± 119.2%)
PP2AC isoforms was knocked down (Fig. 7a–d), respec-
tively. In addition, the knockdown of PP4C expression
significantly (P\ 0.05) elevated Ser63
(1082.0 ± 303.5%) and Ser68 (1101.0 ± 225.9%) phos-
phorylation. However, the phosphorylation of PLM at
Ser63 (Fig. 7g) and Ser68 (Fig. 7h) was unaltered when
PP6C protein expression was attenuated by siRNA-medi-
ated knockdown. Therefore, using selective tools to abro-
gate the expression of individual type 2A catalytic
subunits, our data suggest that not only do both isoforms of
PP2AC regulate the phosphorylation status of PLM in
cardiomyocytes, but so does PP4C. Despite PP6C protein
being highly expressed in the myocardium, it does not
appear to have a role for modulating the phosphorylation
status of PLM in the myocardium.
Regulation of H2A.X phosphorylation by H2O2
in cardiomyocytes
Oxidative stress is considered to be an associative risk
factor for the development of pressure overload-induced
LV hypertrophy [71, 79]. Elevated oxidative stress by
exogenous H2O2 has also been reported to induce DNA
damage (cH2A.X formation) in neonatal cardiomyocytes,
as a consequence of ATM kinase activation [83]. It was,
therefore, important to investigate whether the type 2A
phosphatase-alpha4 signalling axis regulates the formation
of oxidant stress-induced cH2A.X foci in cardiomyocytes.
We have shown that all three type 2A phosphatase catalytic
subunits are expressed in H9c2 cardiomyocytes and they
have all been shown to dephosphorylate cH2A.X foci in
non-myocytes [13, 67, 84]. However, the possibility of
redundant phosphatase capacity within this system was
addressed by knocking down the expression of just one of
the catalytic subunits (PP6C) by [90% (Fig. 8a). Car-
diomyocytes were then subjected to elevated levels of
cellular oxidant stress (exogenous H2O2) at a concentration
(300 lM) that induced pro-apoptotic signalling (Supple-
mental Figure S8) and increased the formation of cH2A.X
foci in control-treated cells (3.4-fold). The formation of
H2O2-induced cH2A.X foci (Fig. 8b) and expression of
non-phosphorylated H2A.X protein (Fig. 8c) were not
significantly altered by the knockdown of PP6C expres-
sion. However, when expression of alpha4 protein ([95%)
was knocked down (Fig. 8d), the formation of cH2A.X foci
in cardiomyocytes in response to H2O2 was completely
abolished (Fig. 8e), which may have been dependent upon
the significant reduction of total non-phosphorylated
H2A.X protein in response to the knockdown of alpha4
protein expression (Fig. 8f). The phosphorylation status of
H2A.X was also normalised to non-phosphorylated H2A.X
(Supplemental Figure S9). It is worth noting that elevated
levels of oxidant stress could differentially affect the
expression of type 2A protein phosphatase catalytic sub-
units and alpha4 as determined by western analysis. The
protein expression of both PP4C and PP6C was
Fig. 4 Expression of type 2A protein phosphatase catalytic subunits
and alpha4 in LV hypertrophied tissue. Murine LV hypertrophy
expressed as LV weight (LVW)/tibia length (TL) was induced by
28 days of TAC-mediated pressure overload (a). Protein expression
and quantification of type 2A protein phosphatase catalytic subunits
(PP2AC, PP4C, and PP6C) in LV tissue from both SHAM (n = 4)
and TAC (n = 6) operated mice, was determined by western analysis
using subunit-specific antibodies, where ‘‘H’’ indicates an H9c2 lysate
positive control sample. PP6C immunoblot contains a splice (black
line) to maintain formatting within the set of data (b–e). Protein
expression of alpha4 in SHAM (n = 4) and TAC (n = 6) operated
LV tissue was determined by western analysis with a polyclonal
antibody to alpha4 (f). Protein expression was normalised to actin in
each sample. All data represent mean values ± SEM, *P\ 0.05 vs.
SHAM
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significantly (P\ 0.05) reduced by exposure of car-
diomyocytes to H2O2 (300 lM); however, the expression
of PP2AC and alpha4 protein was unaltered (Supplemental
Figure S10). Interestingly, PP6C has been shown to regu-
late levels of cH2A.X in non-myocytes; however, the
knockdown of PP6C in cardiomyocytes was unable to
significantly alter the formation of cH2A.X foci in the
absence or presence of H2O2, thereby suggesting that the
formation of cH2A.X in response to H2O2 does not involve
PP6C, but is highly dependent on alpha4 protein expres-
sion. Furthermore, the expression of H2A.X histone protein
was highly dependent upon the expression of alpha4 and
not PP6C.
Discussion
The original findings of the present study are that rat car-
diomyocytes (embryonic, neonatal, and adult) express all
type 2A protein phosphatases (PP2AC, PP4C and PP6C) at
the mRNA level. We show that ARVM have relatively low
levels of PP4C mRNA expression and undetectable levels
of PP4C protein expression as determined by standard
western analysis. The protein expression of all type 2A
protein phosphatase catalytic subunits is differentially
regulated by the 26S proteasome in ARVM and our data
confirm that expression of the alpha4 protein is funda-
mentally important in maintaining type 2A protein phos-
phatase catalytic subunit protein expression in
cardiomyocytes. Furthermore, this study also demonstrates
that LV hypertrophy is not only associated with increased
expression of PP2AC, but also alpha4, which we believe to
be inextricably linked. Despite expression levels of PP6C
protein being unaltered in hypertrophied tissue, our data
show that LV hypertrophied tissue is associated with (1)
increased expression of SAP1, (2) decreased expression of
SAP2, and (3) increased expression of ANKRD28/44 PP6C
regulatory proteins. Importantly, we also show that the
cellular association of PP2AC and PP6C subunits with
alpha4 protein was either unchanged or significantly
decreased in the hypertrophied myocardium, respectively.
The phosphorylation of phospholemman at Ser63 and
Ser68 was dependent upon PP2ACa/b and PP4C, but not
PP6C. Furthermore, the phosphorylation of a core histone
(H2A) variant H2A.X on Ser139 (cH2A.X), a hallmark of
DNA damage, was increased in response to oxidant stress
(exogenous H2O2) in a PP6C-independent and alpha4-de-
pendent manner.
Fig. 5 Expression of PP6C regulatory proteins in LV hypertrophied
tissue. The expression of PP6C regulatory subunits SAP1-3 and
ANKRD28/44/52 proteins was determined in LV tissue obtained from
both SHAM (n = 4) and TAC (n = 6) operated mice, by western
analysis with antibodies specific to SAP1-3 (a–d) and ANKRD28/44/
52 (e–h) proteins. Protein expression was normalised to actin in each
sample. All data represent mean values ± SEM, *P\ 0.05 vs.
SHAM
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This study describes for the first time the comparative
expression levels (mRNA and protein) of all type 2A
protein phosphatase catalytic subunits (PP2ACa/b, PP4C,
and PP6C) in cardiomyocytes. We show that the mRNA
encoding all four catalytic subunits is present in H9c2
cardiomyocytes, NRVMs, and ARVMs. The expression of
PP2ACb mRNA appears to be most abundant in embryonic
H9c2 cardiomyocytes and NRVMs, whereas PP2ACb
mRNA in ARVM was significantly lower than PP2ACa
mRNA, which suggests that PP2ACb gene transcription is
developmentally regulated in cardiomyocytes. In our study,
levels of PP4C mRNA was significantly higher than PP6C
Fig. 6 Association of PP2AC and PP6C with alpha4 in LV
hypertrophied tissue. Immunoprecipitation of alpha4 protein and
association with PP2AC or PP6C in LV tissue obtained from SHAM
(n = 4) and TAC (n = 4) operated mice was performed using a
polyclonal anti-alpha4 antibody in combination with protein A
paramagnetic beads. Alpha4 protein content in the input pre-
immunoprecipitate (pre-IP) and post-immunoprecipitate (post-IP)
lysate was determined by western analysis using a monoclonal anti-
alpha4 antibody (a). Alpha4 protein content in control (rabbit IgG and
PBS) and anti-alpha4 immunoprecipitates from LV tissue lysate of
SHAM (n = 4) and TAC (n = 4) operated mice was determined by
western analysis using a monoclonal anti-alpha4 antibody and
quantified by densitometry (b). PP2AC and PP6C protein content in
lysates before (pre-IP) and after (post-IP) immunoprecipitation of
alpha4 protein was determined by western analysis with subunit-
specific anti-PP2AC (c) and anti-PP6C (d) antibodies. PP2AC and
PP6C protein content in control (rabbit IgG and PBS) and anti-alpha4
immunoprecipitates from LV tissue lysate of SHAM (n = 4) and
TAC (n = 4) operated mice was determined by probing immuno-
complexes with subunit-specific anti-PP2AC (e) and anti-PP6C
(f) antibodies. Immunoprecipitated PP2AC and PP6C were nor-
malised to the alpha4 content of the immunoprecipitates and
expressed relative to SHAM control tissue. PP2AC and PP6C
immunoblots were spliced (black line) to aid clarity. *P\ 0.05 vs.
SHAM
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mRNA in H9c2 rat cardiomyocytes, equivalent in NRVMs,
but significantly lower than in ARVMs. This suggests that
expression of the PP4C gene is developmentally regulated
in the myocardium as in other tissues [32]. Our data sug-
gest that type 2A catalytic subunit gene expression is
qualitatively similar in H9c2 cardiomyocytes and NRVMs.
As these cells come from different strains of the same
species (rat), the data suggest that there are no strain-de-
pendent differences in gene expression. In addition, despite
PP2AC, PP4C and PP6C protein expression being present
in both H9c2 cardiomyocytes (Fig. 1d) and NRVM (Sup-
plemental Figure S1), PP4C protein was consistently
absent in adult heart tissue (rat or mouse), which is sup-
ported by observations made by Kloeker et al. [39]. Fur-
thermore, we were only able to observe PP4C protein
expression in ARVM upon inhibition of the 26S protea-
some with MG132, thereby suggesting that levels of PP4C
protein expression in adult tissue were both transcription-
ally (low mRNA) and post-translationally regulated. We
believe that our data reveal an additional developmental
difference relevant to the expression of PP4C protein,
which may involve proteasomal targeting and degradation
of PP4C in the adult myocardium. PP6C mRNA appears to
be expressed to a similar degree in both ARVM and H9c2
cardiomyocytes; however, PP6C protein expression is
significantly higher in ARVM than in H9c2 cardiomy-
ocytes. This is suggestive that PP6C protein may be post-
transcriptionally regulated or its stability altered in the
adult myocardium. It is worth noting, however, that mild
(1 lM) non-toxic inhibition of the 26S proteasome by
MG132 did not significantly alter PP6C protein expression.
Several studies have shown that the non-catalytic regula-
tory protein alpha4 associates with type 2A catalytic subunits
[11, 50, 54, 56]. In non-myocytes, the ablation of alpha4
Fig. 7 Regulation of phospholemman phosphorylation by type 2A
protein phosphatases in cardiomyocytes. H9c2 cardiomyocytes were
transfected with non-targeting control siRNA (ctr), rat-specific
PP2ACa-siRNA (siPP2ACa), PP2ACb-siRNA (siPP2ACb), PP4C-
siRNA (siPP4C), or PP6C-siRNA (siPP6C) for 4 days. Phosphory-
lation of PLM at Ser63 (a, c, e, g) or Ser68 (b, d, f, h) was determined
by standard western analysis using rabbit polyclonal anti-phospho-
PLM-Ser63, anti-phospho-PLM-Ser68, and rabbit monoclonal anti-
PLM antibodies. Protein levels were quantified by densitometry and
were normalised to total PLM in each sample. All data represent
mean values ± SEM of six individual experiments. Statistical
comparison was made by a two-tailed unpaired Student’s t test;
*P\ 0.05 vs. ctr
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protein expression has been reported to result in the indirect
knockdown of PP2AC, PP4C, and PP6C protein expression
[41, 44], thereby suggesting that cellular expression of the
type 2A catalytic subunits is highly dependent on expression
of alpha4 in cells. This indirect knockdown of type 2A cat-
alytic subunits is underpinned by reports confirming that
alpha4 contains an ubiquitin-interacting motif (UIM) that is
thought to ‘‘protect’’ PP2AC from proteasome-mediated
degradation, by diverting E3 ligase-mediated ubiquitination
away from PP2AC [45, 49, 50]. This ‘‘protective’’ function of
alpha4 protein towards PP2AC was confirmed to exist in
cardiomyocytes by our data in Fig. 3, whereby the knock-
down of alpha4 protein expression by siRNA also signifi-
cantly attenuated the expression of type 2A catalytic subunits
(PP2AC, PP4C, and PP6C). The significant development of
LV hypertrophy in response to pressure overload as shown in
Fig. 4a and Supplemental Figure S6, was sufficient to sig-
nificantly increase PP2ACsubunit expression by 65.2% in our
studies, which supports the observations of previous reports
that the diseased myocardium is causally associated with
enhanced PP2AC expression [18, 25] and activity [1, 7]. It is
worth noting, that in a similar model of pressure overload
where transaortic constriction was also maintained for
4 weeks, the protein expression of a non-type 2A protein
phosphatase, the dual-specificity phosphatase 14 (Dusp14)
was conversely reduced in hypertrophied tissue [46]. Fur-
thermore, rapid pacing has been shown to also decrease the
protein expression of another dual-specificity phosphatase
MAPK phosphatase 1 (MKP1) [22]. This suggests that the
expression of functionally distinct phosphatase families may
be differentially altered in the diseased myocardium. How-
ever, the nature of the elevated PP2AC protein expression in
the diseased myocardium is poorly understood. Gergs et al.
[25] reported that the overexpression of PP2AC in the murine
myocardium induced LVhypertrophy butwithout any change
in the expression of alpha4, thereby suggesting that PP2AC
protein expression per se does not regulate expression of
alpha4 protein. However, in our study, expression of alpha4
proteinwas significantly increased in hypertrophied tissue and
a significance of this increase may explain why there was a
concomitant significant increase in PP2AC in hypertrophied
tissue. Hence, our study suggests that the pressure overload-
induced increase in alpha4 protein expression may have pro-
tected PP2AC from degradation by the 26S proteasome (dis-
cussed earlier) and consequently augmented the amount of
PP2ACprotein in hypertrophied tissue as seen in other studies
[18, 25]. It is worth noting that in non-myocytes, alpha4
overexpression can significantly increase ectopic PP2AC
overexpression [41, 45, 82]; however, overexpression of
alpha4 per se does not affect native levels of PP2AC
Fig. 8 Regulation of H2O2-induced H2A.X phosphorylation by PP6C
or alpha4 in cardiomyocytes. H9c2 cardiomyocytes were transfected
with non-targeting control siRNA (ctr) or rat PP6C-specific siRNA
(si) to knockdown the expression of PP6C protein, which was
confirmed by standard western analysis using an antibody specific to
PP6C (a). Cardiomyocytes transfected with non-targeting control
siRNA or PP6C siRNA were then exposed to vehicle control (-) or
H2O2 (?) for 24 h and phosphorylation of H2A.X at Ser139
(cH2A.X) was determined by standard western analysis (b). Total
H2A.X protein expression was also determined by standard western
analysis in cardiomyocytes following knockdown of PP6C (c).
Cardiomyocytes were also transfected with either non-targeting
control siRNA (ctr) or rat alpha4-specific siRNA (si) and treated as
described above (d–f). Protein expression was quantified by densit-
ometry and where appropriate was then normalised to actin in each
sample. All data represent mean values ± SEM of four individual
experiments, *P\ 0.05 vs. untreated ctr
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expression [41, 50]. We propose that there is an increase in
PP2AC:alpha4 complex formation in cardiac tissue subjected
to pressure overload. Interestingly, alpha4 protein expression
has been found to be elevated in other non-cardiac tissues
undergoing uncontrolled growth [12, 69]. However, an
explanation of why alpha4 protein expression was elevated in
hypertrophied tissue remains an important question that
requires further study.
The role(s) of the other type 2A phosphatase catalytic
subunits (PP4C and PP6C) in cardiovascular pathologies is
currently undefined. The absence of PP4C protein expres-
sion in the adult myocardium precluded us from studying
the expression of PP4C regulatory proteins in the heart and
our data show that protein expression of the PP6C subunit
is not altered by pressure overload-induced hypertrophy.
Hence, we focussed on the subunits that are thought to
regulate targeting and activity of PP6C, which as our data
suggest is abundantly expressed in the adult myocardium.
Evidence suggests that the sit4-associated proteins, SAP1
and SAP2, regulate the phosphorylation of H2A.X in either
positive or negative manners, respectively. Studies have
shown that SAP1/PP6C protein complexes associate with,
dephosphorylate and activate DNA-PK [31, 51], which
then phosphorylates the nuclear histone (H2A) variant
H2A.X at Ser139 (cH2A.X) [8]. On the other hand, SAP2/
PP6C protein has been shown to dephosphorylate cH2A.X
following DNA damage [84]. In our studies, novel data
suggest that even though PP6C protein expression was
unaltered in hypertrophied tissue, protein expression of
PP6C regulatory proteins SAP1 and SAP2 was either
increased or reduced, respectively. This would argue for
increased levels of cH2A.X in hypertrophied tissue, which,
in our studies, was not the case (Supplemental Figure S5).
To date, the role(s) of ANKRD28/44/52 proteins in both
cardiac health and disease are undefined. This is the first
study to report the existence of the PP6C regulatory
ANKRD proteins in the heart, and it is, therefore, difficult
to ascribe any consequence of the elevated ANKRD28 or
ANKRD44 protein expression observed in the hypertro-
phied myocardium. Seeing as ANKRD proteins bind SAPs
which themselves are associated with PP6C subunits [77],
one can only infer that the increased expression of
ANKRD28 and ANKRD42 proteins may mediate
increased localisation/activity of PP6C within the hyper-
trophied myocardium. In our study, elevated ANKRD28/44
protein expression which would promote cH2A.X
dephosphorylation may override the effects of altered
SAP1 & SAP2 expression which might promote H2A.X
phosphorylation, thereby contributing to the lower, albeit
non-significant, levels of cH2A.X in hypertrophied tissue
(Supplemental Figure S5).
The association between alpha4 protein and PP6C is
known to inhibit PP6C activity in vitro [56, 63] and in
yeast [35]. Recent evidence suggests that a significantly
higher proportion of cellular PP6C, compared to PP2AC
or PP4C, is found associated with alpha4 protein in
HEK293T cells [44]. These data partly agree with what
we have observed, except that alpha4 protein also
associates with a significant proportion of PP2AC in the
adult myocardium. Furthermore, our study describes
novel observations regarding the association between
alpha4 and type 2A catalytic subunits in diseased tissue.
Although the association between alpha4 and PP2AC
was unaltered, despite an increase in the expression of
both proteins in hypertrophied myocardium, the associ-
ation between alpha4 and PP6C was significantly
reduced. A decreased association between alpha4 and
PP6C protein would be expected to perhaps disinhibit
PP6C, thereby leading to enhanced PP6C activity.
Hence, disinhibited PP6C combined with elevated levels
of ANKRD28/44 protein expression in hypertrophied
tissue may contribute to the dephosphorylation of sub-
strates such as H2A.X in hypertrophied tissue (Supple-
mental Figure S5).
PP2AC has been implicated as a protein phosphatase
that regulates the activity of many ion transporters involved
in cardiomyocyte excitation–contraction coupling. One
such ion transporter is the sodium pump, whose activity is
regulated through its association with the phosphoprotein
PLM [17]. The phosphorylation of PLM on Ser63 and
Ser68 relieves its inhibitory activity towards the sodium
pump and thereby accelerates the efflux of sodium ions
from the cardiomyocyte (see review by Pavlovic et al.
[62]). Hence, hypophosphorylation of PLM at Ser63 and
ser68 would be expected to decrease sodium pump activity,
reduce sodium efflux, and as a consequence augment
intracellular sodium load within the cardiomyocyte. In
hypertrophied left ventricular tissue, Boguslavskyi et al.
reported that the phosphorylation of PLM at both Ser63
and Ser68 was significantly reduced, thereby contributing
to elevated intracellular sodium levels [6]. Our own data
(Fig. 7) suggest that not only PP2ACa/b, but also PP4C
can induce the dephosphorylation of PLM at Ser63 and
Ser68 in cardiomyocytes. In the context of myocardial
hypertrophy, as PP4C is not expressed in adult myocardial
tissue, it is, therefore, unlikely to contribute to regulating
the phosphorylation status of PLM in adult hypertrophied
LV tissue. Furthermore, despite having shown that the
expression of PP6C regulatory proteins (ANKRD28/44) is
elevated in LV hypertrophied tissue and our catalytic
subunit knockdown data suggest that PP6C does not
dephosphorylate PLM, it is unlikely that PP6C plays any
significant role in regulating the phosphorylation status of
Ser63 and Ser68 of PLM in hypertrophied LV myo-
cardium. It is, therefore, very likely that the only type 2A
protein phosphatase isoforms that regulate the
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phosphorylation of PLM in the healthy or hypertrophied
heart are PP2AC a and b.
The phosphorylation of H2A.X at Ser139 and formation
of cH2A.X foci are considered a hallmark of DNA damage
in cells [48]. Oxidant stress is a potent inducer of DNA
damage and consequent formation of cH2A.X foci in non-
myocytes [38, 66]. Furthermore, H2O2 induces DNA
damage (cH2A.X formation) in neonatal cardiomyocytes,
as a consequence of ATM kinase activation [83]. In sup-
port, our data show that cellular oxidant stress (300 lM
H2O2) not only increased levels of cH2A.X foci, but also
induced apoptotic signalling in cardiomyocytes by pro-
moting the cleavage and activation of (pro)caspase 3 and
inactivation of a caspase 3 substrate PARP1 (Supplemental
Figure S8). Despite PP6C being implicated in regulating
the formation of cH2A.X foci in non-myocytes [21, 84],
the knockdown of PP6C protein expression in cardiomy-
ocytes did not increase the basal formation of cH2A.X foci
or augment those formed in response to H2O2. This sug-
gests that either PP6C does not target cH2A.X in car-
diomyocytes or that there is sufficient redundant activity of
other type 2A catalytic subunits (PP2AC and PP4C)
towards cH2A.X to compensate for the siRNA-induced
knockdown of PP6C. Our data suggest that PP2AC may be
the probable candidate as its expression is unaltered by
H2O2, whereas PP4C expression was significantly attenu-
ated by exposure to H2O2 (Supplemental Figure S10). The
differential effect of oxidant stress on type 2A catalytic
subunits is supported (in part) by a lack of effect of H2O2
on alpha4 expression. The knockdown of alpha4 expres-
sion was not only shown to attenuate the expression of all
type 2A catalytic subunits but to significantly decrease the
formation of cH2A.X foci in untreated cardiomyocytes and
those exposed to H2O2. This was unexpected as reports
have indicated that all type 2A catalytic subunits are known
to target cH2A.X [13, 21, 67], and indirect knockdown of
these catalytic subunits by silencing the expression of
alpha4 protein should have increased levels of cH2A.X as
reported by Kong et al. [41]. Interestingly, core histones
(H2A) in cells exposed to significant stress and consequent
DNA damage can be degraded by the PA200/Bim10-con-
taining proteasome [65], so that damaged DNA can be
unravelled and repaired by the DNA damage repair
response. We propose that, in our study, the alpha4
knockdown and consequent loss of type 2A catalytic sub-
units constituted a severe insult. We propose that the
severity of this insult was sufficient to induce the degra-
dation of H2A.X protein and prevent cells from forming
cH2A.X foci, thereby failing to undergo DNA repair to
maintain genomic stability and cellular integrity. Hyper-
trophic tissue might be expected to exhibit elevated levels
of cH2A.X foci, as it is associated with higher levels of
oxidative stress [71, 79]. However, our data suggest that
this is not the case and that cH2A.X foci levels were if
anything slightly lower in hypertrophied tissue. Maintain-
ing low levels of cH2A.X foci may well delay DNA repair
in myocytes subjected to a higher degree of cell stress and
may, therefore, predispose these myocytes to eventual cell
injury and death.
In conclusion, these studies indicate that the type 2A
protein phosphatases are differentially regulated in both the
healthy and hypertrophied myocardium. The data suggest
that pressure overload-induced hypertrophy is associated
with (1) altered expression of type 2A protein phosphatases
and their regulatory subunits and (2) an increase in
expression of their non-catalytic regulatory protein alpha4.
Interestingly, PP6C was shown to associate with alpha4
protein in adult cardiac tissue as in other cell types, but its
association with alpha4 protein was significantly reduced
in hypertrophied tissue. In addition, despite elevated
expression of both PP2AC and alpha4 protein, the associ-
ation between PP2AC with alpha4 protein was unaltered in
hypertrophied tissue. The phosphorylation status of PLM at
Ser63 and Ser68 is regulated by PP2ACa, PP2ACb, and
PP4C. The expression of the core histone H2A.X and
formation of cH2A.X foci in response to H2O2 are not
regulated by PP6C, but is highly dependent on alpha4
protein expression in cardiomyocytes.
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